# A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

> **NCT00349193** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 306 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** laquinimod 0.3
- **DRUG:** laquinimod 0.6
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00349193
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2006-06
- **Final completion:** 2006-08
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2011-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349193, "A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00349193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*